MRK | Weekly | Haru Insights

The European Commission’s approval of KEYTRUDA in combination with Padcev (pomalidomide + daratumumab) as a neoadjuvant therapy for muscle-invasive bladder cancer (MIBC), backed by transformative Phase 3 data showing a 60% improvement in event-free survival and a 50% reduction in death risk, marks a pivotal regulatory milestone for Merck’s oncology portfolio.
The FDA’s approval of KEYTRUDA in combination with Trodelvy for first-line treatment of PD-L1-positive triple-negative breast cancer (TNBC) expands Merck’s footprint in a high-unmet-need indication, reinforcing KEYTRUDA’s strategic centrality and unlocking substantial commercial potential.

KEYTRUDA’s neoadjuvant approval in bladder cancer cements Merck’s dominance, establishing a new standard of care with transformative trial data that delivers both clinical breakthroughs and robust commercial momentum in a high-incidence malignancy.
The successful launch of KEYTRUDA + Trodelvy in frontline TNBC offers a highly differentiated, first-in-class option with limited competition—positioning Merck for rapid market penetration and long-term growth in a patient population with dire prognosis.
Merck’s expanding KEYTRUDA-based combination arsenal demonstrates deep R&D execution, with two major approvals this week signaling sustained innovation capacity in immuno-oncology despite patent challenges.
Regulatory momentum across both EU and US markets highlights Merck’s global alignment, enabling simultaneous commercialization and accelerating revenue realization from patented oncology advances.
The clinical superiority shown in Event-Free Survival (60% improvement) in MIBC reinforces investor confidence, suggesting durable pricing power and payer acceptance for high-value immunotherapy regimens.

Merck & Co., Inc. (MRK)[Tv]